CN109045009A - 治疗痛风急性发作的方法 - Google Patents

治疗痛风急性发作的方法 Download PDF

Info

Publication number
CN109045009A
CN109045009A CN201810759998.1A CN201810759998A CN109045009A CN 109045009 A CN109045009 A CN 109045009A CN 201810759998 A CN201810759998 A CN 201810759998A CN 109045009 A CN109045009 A CN 109045009A
Authority
CN
China
Prior art keywords
uric acid
compound
subject
gout
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810759998.1A
Other languages
English (en)
Chinese (zh)
Inventor
布赖恩·爱德华·拉万
戈帕尔·钱德拉·萨哈
布赖恩·K·罗伯茨
查尔斯·A·麦克沃特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyer Tex Ltd By Share Ltd
Shellfish Pharmaceuticals Of Sigma
Original Assignee
Dyer Tex Ltd By Share Ltd
Shellfish Pharmaceuticals Of Sigma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyer Tex Ltd By Share Ltd, Shellfish Pharmaceuticals Of Sigma filed Critical Dyer Tex Ltd By Share Ltd
Priority to CN201810759998.1A priority Critical patent/CN109045009A/zh
Publication of CN109045009A publication Critical patent/CN109045009A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201810759998.1A 2011-11-04 2011-11-04 治疗痛风急性发作的方法 Pending CN109045009A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810759998.1A CN109045009A (zh) 2011-11-04 2011-11-04 治疗痛风急性发作的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201180076190.XA CN104066324A (zh) 2011-11-04 2011-11-04 治疗痛风急性发作的方法
CN201810759998.1A CN109045009A (zh) 2011-11-04 2011-11-04 治疗痛风急性发作的方法
PCT/US2011/059433 WO2013066353A1 (en) 2011-11-04 2011-11-04 Methods for treating gout flares

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180076190.XA Division CN104066324A (zh) 2011-11-04 2011-11-04 治疗痛风急性发作的方法

Publications (1)

Publication Number Publication Date
CN109045009A true CN109045009A (zh) 2018-12-21

Family

ID=48192537

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810759998.1A Pending CN109045009A (zh) 2011-11-04 2011-11-04 治疗痛风急性发作的方法
CN201180076190.XA Pending CN104066324A (zh) 2011-11-04 2011-11-04 治疗痛风急性发作的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180076190.XA Pending CN104066324A (zh) 2011-11-04 2011-11-04 治疗痛风急性发作的方法

Country Status (18)

Country Link
EP (1) EP2775836B8 (https=)
JP (1) JP6008974B2 (https=)
KR (1) KR101848121B1 (https=)
CN (2) CN109045009A (https=)
AU (1) AU2011380510B2 (https=)
BR (1) BR112014010729A2 (https=)
CA (1) CA2859693C (https=)
CL (1) CL2014001157A1 (https=)
DK (1) DK2775836T3 (https=)
EA (1) EA201490928A1 (https=)
ES (1) ES2698396T3 (https=)
IL (1) IL232384A (https=)
MX (1) MX357510B (https=)
NZ (1) NZ624726A (https=)
PH (1) PH12014500990A1 (https=)
PL (1) PL2775836T3 (https=)
SG (1) SG11201401981TA (https=)
WO (1) WO2013066353A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052976T2 (hu) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Urát-oxidáz variáns formái és azok alkalmazása
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
RU2013127313A (ru) 2010-11-16 2014-12-27 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Системы и способы лечения сухого глаза
CN104602686A (zh) * 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN110234340A (zh) * 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
US11446317B2 (en) * 2017-10-26 2022-09-20 Otsuka Pharmaceutical Co., Ltd. Inositol phosphate-containing composition
CN109223707B (zh) * 2018-09-13 2020-12-08 中国药科大学 一种尿酸酶外用凝胶制剂、其制备方法及用途
CN114028584B (zh) * 2021-11-18 2023-09-05 辽宁万嘉医药科技有限公司 一种降尿酸的多酚多元环糊精包合物及其制备方法
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
KR20250085216A (ko) 2023-12-05 2025-06-12 인제대학교 산학협력단 알코올 스프레이를 활용한 환자 냉각장치

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660060A (zh) * 1999-06-04 2005-08-31 麦它波莱克斯股份有限公司 (－)(3－三卤代甲基苯氧基)(4－卤代苯基)乙酸衍生物在治疗高尿酸血症中的应用
CN101918377A (zh) * 2007-11-27 2010-12-15 亚德生化公司 新颖化合物和组合物以及使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624194B1 (en) 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
JP2008538351A (ja) * 2005-03-21 2008-10-23 メタボレックス インコーポレーティッド 癌を含むＰＰＡＲγ反応性疾患の処置または予防における浮腫を回避するための方法
MX2010011603A (es) * 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660060A (zh) * 1999-06-04 2005-08-31 麦它波莱克斯股份有限公司 (－)(3－三卤代甲基苯氧基)(4－卤代苯基)乙酸衍生物在治疗高尿酸血症中的应用
CN101918377A (zh) * 2007-11-27 2010-12-15 亚德生化公司 新颖化合物和组合物以及使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GILBERT B. BLUHM ET AL.: "A Double-blind Study Comparing Halofenate with Probenecid in Gout", 《ARTHRITIS AND RHEUMATISM》 *
匿名: ""Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer"", 《HTTP://WWW.BIO-MEDICINE.ORG/BIOLOGY-TECHNOLOGY-1/METABOLEX-APPOINTS-RAYMOND-URBANSKI-M-D---PH-D--TO-POSITION-OF-CHIEF-MEDICAL-OFFICER-20805-1/》 *
匿名: ""Metabolex Initiates Phase 2 Trial of Arhalofenate"", 《HTTP://WWW.PRNEWSWIRE.COM/NEWS/METABOLEX%2C+INC.》 *

Also Published As

Publication number Publication date
KR101848121B1 (ko) 2018-04-11
EP2775836B8 (en) 2018-10-24
EP2775836A1 (en) 2014-09-17
BR112014010729A2 (pt) 2018-03-20
JP6008974B2 (ja) 2016-10-19
CN104066324A (zh) 2014-09-24
IL232384A (en) 2017-10-31
WO2013066353A1 (en) 2013-05-10
CA2859693A1 (en) 2013-05-10
AU2011380510A1 (en) 2014-05-29
EP2775836A4 (en) 2015-05-20
AU2011380510B2 (en) 2016-05-12
KR20140121384A (ko) 2014-10-15
MX2014005398A (es) 2015-04-08
JP2014532760A (ja) 2014-12-08
EP2775836B1 (en) 2018-09-12
SG11201401981TA (en) 2014-05-29
CA2859693C (en) 2018-05-22
NZ624726A (en) 2016-01-29
IL232384A0 (en) 2014-06-30
EA201490928A1 (ru) 2014-11-28
PH12014500990A1 (en) 2014-08-04
DK2775836T3 (en) 2018-12-03
MX357510B (es) 2018-07-12
CL2014001157A1 (es) 2015-01-16
PL2775836T3 (pl) 2019-02-28
ES2698396T3 (es) 2019-02-04

Similar Documents

Publication Publication Date Title
CN109045009A (zh) 治疗痛风急性发作的方法
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
AU2020290001A1 (en) Casein kinase 1 inhibitors for use in the treatment of diseases related to DUX4 expression such as muscular dystrophy and cancer
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
AU2013245675B2 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
JP6192142B2 (ja) 痛風発赤の治療方法
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181221